HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
GXQPsFSsJe8m1U3L